Metformin HCL
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-21-R-0111
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA Troop Support) has announced a forthcoming solicitation for a national requirements contract to supply Metformin HCL Extended Release (ER) tablets. This presolicitation notice, identified by procurement number SPE2D2-21-R-0111, outlines the agency’s intent to establish a reliable, long-term supply source for Metformin HCL ER, a widely used pharmaceutical for the management of type 2 diabetes.
The scope of this procurement encompasses Metformin HCL ER tablets in two dosage strengths: 500MG and 750MG. The 500MG tablets are to be provided in bottles containing 50, 90, 100, 180, 360, and either 500 or 1000 tablets. The 750MG tablets are required in bottles of 90, 100, 180, and either 500 or 1000 tablets. The contract will be structured as a firm-fixed price, requirements type agreement, featuring a one-year base period with four additional one-year option periods. This arrangement is designed to ensure continuity of supply and price stability for the duration of the contract.
The intended outcome of this procurement is to support the pharmaceutical needs of multiple federal agencies, including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The awarded contractor will serve as a national supply source, fulfilling orders placed through the DLA and VA prime vendor programs. Annual usage estimates for each line item will be detailed in the Schedule of Supplies section of the solicitation, enabling offerors to assess the scale and logistics of the requirement.
Key requirements for this opportunity include the ability to manufacture and supply commercial pharmaceutical preparations in accordance with NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505 (Drugs and Biologicals). The acquisition will be conducted under FAR Part 12, signifying that it is for commercial items and will follow streamlined procurement procedures. The solicitation is unrestricted and fully competitive, welcoming proposals from all qualified sources. There are no set-aside requirements or special socioeconomic considerations specified in this notice.
Interested parties are encouraged to monitor the DLA Bid Board System (DIBBS) and SAM.gov for the official release of the solicitation and any subsequent updates. The projected solicitation date is August 2021, though DLA reserves the right to adjust this timeline as needed. For questions or further information, contractors may contact the primary point of contact, Christopher Newman ([email protected], 215-737-2905), or the secondary contact, Jason Wray ([email protected], 215-737-0614).
This opportunity represents a significant and stable contract for suppliers capable of meeting the rigorous requirements of federal pharmaceutical procurement. Contractors with experience in large-scale, commercial pharmaceutical manufacturing and distribution are encouraged to review the solicitation upon release and consider submitting a proposal.